https://www.selleckchem.com/pr....oducts/valemetostat-
482; 95 % CI 0.343-0.678, p0.001); and 60% less frequently recommended increasing the PA (OR, 0.408; 95 % CI 0.292-0.570, p0.001).Conclusion Most of the surveyed were aware of the benefits of PA for prevention and treatment of CNID, however, they related the mechanism of this effect only with weight loss. The most frequently mentioned barriers to behavioral risk counseling were uncertainty about whether such counseling was within the physician's professional competence, lack of time, lack of confidence in the provis
Like
Comment
Share
